CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nventa Biopharmaceuticals Corp. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nventa Biopharmaceuticals Corp.
Suite 180, 9381 Judicial Drive
Phone: (858) 202-4900p:858 202-4900 SAN DIEGO, CA  92121  United States Ticker: NVNNVN

This company was Merged or Acquired on 5/22/2009.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Nventa Biopharmaceuticals Corporation (Nventa) is a biopharmaceutical company engaged in developing therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). Its clinical focus is on the development of the HspE7 + Poly-ICLC, which contains the CoVal fusion protein HspE7 co-administered with the adjuvant, Poly-ICLC, a toll-like Receptor 3 (TLR3) agonist. HspE7 + Poly-ICLC are designed to treat precancerous and cancerous lesions caused by the HPV. HspE7 is derived from the Company’s platform technology that uses the deoxyribonucleic acid technology to fuse stress proteins to disease-specific antigens that invoke immune system responses. It has also developed the vaccine adjuvant, Poly IC-Poly Arginine (Poly-ICR) and a manufacturing process for Poly-ICR that has a potential for use in both therapeutic and prophylactic vaccines. In May 2009, Nventa amalgamated with a wholly owned subsidiary of Akela Pharma Inc.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/200912/31/2008YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Director, Finance KendraBerger 47
Executive VP, Research & Development Marvin I.Siegle
Director, Investor Relations DonnaSlade
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Nventa Biopharmaceuticals Corp.
NVN
Stressgen Biotechnologies
Stressgen Biotechnologies Corporation

General Information
Number of Employees: 27 (As of 12/31/2005)
Outstanding Shares: 261,210,901 (As of 5/13/2009)
Shareholders: 13,000
Stock Exchange: TSE
Fax Number: (858) 450-6849


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023